05/14/2021 in the clinical study according to the AM217-03 protocol "Multicenter randomized prospective open-label clinical study to investigate the safety and efficacy of Amidine hydrochloride (DD217) as a means of preventing thrombotic complications in hospitalized patients diagnosed with COVID-19" 400-th patient was included (randomized). The enrollment of patients for the study has been completed.
